

Statement of Discontinuation of the study	
Name of Company: Sunovion Pharmaceuticals, Inc.	
Study No: EudraCT 2016-000636-18/ Sunovion Protocol ID CTH-300	
Product: APL-130277	
Title : A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)	
Phase: 3	
Study Period: NA	
Centres: NA	
Number of Subjects: 0	
Publications: NA	
Statement on discontinuation of the study: Discontinued by Sunovion Pharmaceuticals Inc., .prior to subjects entering the study, therefore no results / data are available.	